Vulvovaginal Disease

A case study on diagnosis and management. Could you recognize this rare condition?

Could you recognize this rare vulvar condition?

The etiology of this condition is unclear but is consistent with a loss of the normal vaginal flora and increase in inflammation.

This vulvar infection rarely is seen but presents an intriguing case.

Could you recognize this rare condition?

Considerable heterogeneity exists in reported outcomes and measures used in clinical trials of treatments for genitourinary syndrome of menopause (GSM), which impacts between 40% and 60% of postmenopausal women, according to a systematic review in the journal Menopause.

Results of a nationally representative study indicate that many young women receive bimanual pelvic exams (BPEs) and Pap tests that may be unnecessary, and not in compliance with the latest guidance from the American College of Obstetricians and Gynecologists (ACOG).

Candida albicans is the most common etiology for VCC and this study looked at what factors are associated with its molecular detection.

Recurrent or chronic vulvovaginitis is frustrating to patients and a burden to the health care system. Here is a guide to addressing it.

Would you be able to recognize this diagnosis in your practice?

For postmenopausal women with at least one vulvovaginal atrophy (VVA) symptom, the presence of physician-confirmed VVA is linked to significant impaired sexual function, according to a study from the European Vulvovaginal Epidemiological Survey (EVES).

A diagnosis of vulvovaginal atrophy (VVA) in breast cancer survivors is associated with a significant increase in the burden of illness and social costs, according to an Italian Delphi Panel in the journal Supportive Care in Cancer. These findings are primarily due to a rise in comorbidities and resource utilization, but adequate treatment might reduce the impact of the condition.

New research indicates having at least one symptom of vulvovaginal atrophy is linked to significant impaired sexual function for postmenopausal women.

Published research from Sexually Transmitted Diseases indicates a woman’s risk of vulvovaginal candidiasis could be increased by certain personal behaviors as well as the composition of her vaginal microbiota.

Although nearly half of postmenopausal women reported having vulvovaginal symptoms (VVS), only a minority discussed their symptoms during a well-woman visit with a primary care provider or gynecologist, according to recent survey analysis.

The safety and efficacy of targeting vulvovaginal tissues are the topic of this committee opinion.

The experimental agent TX-004HR effectively improved the vaginal mucosa of postmenopausal women with vulvovaginal atrophy (VVA) and reduced moderate-to-severe dyspareunia and vaginal dryness compared to placebo, according to results of a trial.

A small study shows that treatment with CO2 laser induces histological changes in the epithelium and lamina propria that may result in improvement in symptoms associated with vulvovaginal atrophy (VVA).

Results of a randomized clinical trial (RCT) suggest that over-the-counter moisturizer may be just as effective as vaginal estrogen tablets for treatment of vulvovaginal symptoms (VVS) in postmenopausal women. Plus: Does a Mediterranean diet help protect bones in postmenopausal women? Also: Metformin, an oral diabetes medication, seems to reduce the likelihood of late miscarriage and premature birth in women with polycystic ovary syndrome (PCOS), according to results of a multicenter study.